ARDX Stock Overview
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ardelyx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.44 |
| 52 Week High | US$10.13 |
| 52 Week Low | US$3.16 |
| Beta | 0.82 |
| 1 Month Change | -19.70% |
| 3 Month Change | -22.22% |
| 1 Year Change | 34.73% |
| 3 Year Change | -21.37% |
| 5 Year Change | 93.98% |
| Change since IPO | -54.36% |
Recent News & Updates
Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing
Apr 17
Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Mar 13Recent updates
Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing
Apr 17Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Mar 13Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 24Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
Feb 20Ardelyx's XPHOZAH Still An Afterthought To The Pros
Jan 31Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement
Jan 10Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price
Jan 04Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt
Dec 14Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 03Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt
Jul 31Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now
Apr 17Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Mar 30Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Dec 14What To Expect For Ardelyx In The Coming Month
Oct 18Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position
Oct 04Ardelyx secures $20M financial deal with HealthCare Royalty on tenapanor potential sale
Jun 30Ardelyx Is Down, Long Live Ardelyx
Jan 28Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher
Dec 02Ardelyx: Indecisive Regulators, Frustrated Company, Gruelling Wait For Investors
Oct 25Ardelyx: Is There Any Value Left After The Unexpected CRL?
Aug 02Shareholder Returns
| ARDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.6% | -4.7% | -3.7% |
| 1Y | 34.7% | -2.7% | 20.2% |
Return vs Industry: ARDX exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: ARDX exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| ARDX volatility | |
|---|---|
| ARDX Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARDX's share price has been volatile over the past 3 months.
Volatility Over Time: ARDX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 267 | Mike Raab | www.ardelyx.com |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder.
Ardelyx, Inc. Fundamentals Summary
| ARDX fundamental statistics | |
|---|---|
| Market cap | US$1.50b |
| Earnings (TTM) | -US$66.07m |
| Revenue (TTM) | US$124.46m |
12.0x
P/S Ratio-22.7x
P/E RatioIs ARDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARDX income statement (TTM) | |
|---|---|
| Revenue | US$124.46m |
| Cost of Revenue | US$53.33m |
| Gross Profit | US$71.13m |
| Other Expenses | US$137.19m |
| Earnings | -US$66.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 57.15% |
| Net Profit Margin | -53.08% |
| Debt/Equity Ratio | 42.0% |
How did ARDX perform over the long term?
See historical performance and comparison